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Abstract
Background: Myopia-related maculopathy is one of the leading causes of blindness in the world. The prevalence
of myopia has been reported as high as 90 % in some Asian countries. Therefore, controlling myopia progression is
an urgent public issue. The purpose of this study is to evaluate the effects of topical atropine with different
concentrations on intraocular pressure measurements and myopia progression in school-aged children in Taiwan.
Methods: Fifty-six myopic children were divided into three groups: 32 children were treated with 0.125 % atropine
eyedrop; 12 of them were treated with 0.25 % atropine eye drop and another 12 served as a control group. IOP,
auto-refractor and manifest refraction were measured at baseline and every 3 months following treatment for one year.
Results: There were no significant differences for the mean age, gender and baseline IOPs among the three groups.
During the follow up period, no significant IOP difference was found among three groups. The change between final
and baseline mean IOPs also revealed no significant differences: 0.54 mmHg, −1.28 mmHg, −0.33 mmHg for the 0.
125 % atropine, 0.25 % atropine and control groups. The baseline mean spherical equivalent similarly did not differ
significantly among groups but the control group showed a significant myopic progression compared to the 0.125 %
atropine group 6 months after treatment, and persisted for one year. The change between final and baseline mean
spherical equivalents were −0.05 D, 0 D, −1.05 D for the 0.125 % atropine, 0.25 % atropine and control groups, with
both atropine-treated groups showing significant myopic retardation compared to the control group.
Conclusions: Topical use of low concentration atropine for one year does not induce ocular hypertension and is
effective for retarding myopic progression. However, further large scale studies with longer follow up period is
necessary to validate the long term safety and efficacy.
Trial registration: ISRCTN33002849, 2016/01/19, retrospectively registered.
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Background
Myopia is a disease that was described two thousand
years ago, and some physicians in Italy in the 16th cen-
tury even started to use bifocal lenses as a tool to help
people with myopia to see more clearly [1]. Currently,
multiple interventions or management are designed to
control the progression of myopia. Common effective
methods for retarding myopic progression include
spectacles (bifocals and multi-focal), ocular hypotensive
medications, and contact lenses (including orthokeratol-
ogy lenses) [1–3]. Atropine, a muscarinic receptor antag-
onist, has been successfully used to prevent progression
of myopia in Taiwan since 1997 [4] and several clinical
trials also demonstrated its effectiveness for reducing
myopic progression compared with other medications
and managements [1, 5–9]. In fact, topical atropine has
become a mainstream of myopic treatment throughout
eastern and south-eastern Asia [1, 5, 6, 8, 9].
However, some people suspect that the side effects
caused by atropine will harm eyes. The side effects of
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topical atropine can be divided into two types: short-
term and long-term effects. The short-term side effects
include red eyes, photophobia, blurred vision, allergic
dermatitis, risk of increase intraocular pressure (IOP)
and angle closure glaucoma [1, 10–12]. The develop-
ment of drug-induced acute angle closure glaucoma
(AACG) by atropine was reported by Lachker et al. [10]
but Greensteinet al. [13] pointed out that anti-
muscarinic drugs such as atropine will not contribute to
AACG unless there are predisposing factors such as a
shallow anterior chamber and pupil-dilating medica-
tions. However, whether atropine leads to elevated intra-
ocular pressure remains uncertain. The long-term side
effects of atropine is also a mystery, though some pro-
posed that prolonged ultraviolet light exposure due to
the mydriatic effect of atropine could lead to several
types of ocular damage, such as retinal vascular disease
and cataract formation [14, 15]. In addition, previous re-
ports also demonstrated that atropine may lead to drug-
induced amnesia, impaired memory function, somnolence
and seizure [16–18] so long-term administration should
be cautious. Yet cataract or retinal diseases has not been
proven in previous studies which continuously applied
atropine with a follow up of 2 years [5, 12]. However, the
safety profile of long-term atropine administration
certainly deserves large scale and long term surveys.
Still, the relationship between the concentration of at-
ropine and its effect on retarding myopia has not been
elucidated. One study revealed that topical atropine with
1 % concentration is an effective method to prevent my-
opic progression; [6] however, other studies demon-
strated that myopia could be successfully retarded with
low concentration atropine eye drops, ranging from
0.01 % to 0.1 % [19, 20]. For these reasons, further evalu-
ation of the effect of different concentrations of topical
atropine on myopia progression is necessary.
Therefore, the aim of this study is to evaluate the ef-
fect of different concentrations of topical atropine on
retarding the progression of low myopia and the mea-




This prospective, interventional, longitudinal and non-
randomized study was conducted at Keelung Chang
Gung Memorial Hospital, Taiwan. The study group con-
sisted of 56 children in Northern Taiwan ranging in age
from 6 to 12 years. The exclusion criteria included: [1]
congenital eye disorder, [2] any disease influence the
cornea, lens or retina, [3] best correct visual acuity < 20/
25 using the Snellen chart, [4] primary intraocular pres-
sure above 21 mmHg, [5] atropine application within
6 months before enrollment, and [6] patients who could
understand the details of this study or could not adhere
to the follow up schedule. Patients with a refractive error
less than −3.0 diopters (D) were enrolled in this study
and only the right eye of each subject was analyzed to
prevent effect of atropine on the contra-lateral eye. For
those participants who were willing to receive atropine
treatment, we randomly assigned them to either 0.125 %
atropine group or 0.25 % atropine group by drawing lots.
Those who preferred spectacles for correcting myopia
were enrolled in the control group without any eyedrop
use during the study. After removing those participants
that loss follow-up or being absent in at least 1 clinic
visiting, we divided the participants into three groups.
The first group, treated with 0.125 % atropine, consisted
of 32 children (17 boys and 15 girls); the second group
using 0.25 % atropine included 12 children (4 boys and 8
girls); and an additional 12 children (6 boys and 6 girls)
in the control group. The intraocular pressures and
spherical equivalent were measured every 3 months dur-
ing the study period for one year.
Atropine administration
Two topical atropine sulphate eye drops were used in
this study: 0.125 % and 0.25 % (both from Wu-Fu La-
boratories Co, Ltd, Yilan, Taiwan). The concentration we
used was the original concentration from the pharmaco-
logical corporation. No dilution or condensation hap-
pened during the whole study and no patient shared the
same bottle of atropine. The research program was
halted if severe allergic reaction happened to the pa-
tients, and the proper management was subsequently ar-
ranged by medical professionals. The control group did
not receive any placebo eye drop in this study.
Ocular examination
All children were examined by the same technician (Y. F.
Lin) for the measurement of intraocular pressure and the
manifest refraction examinations during the study period.
The slit-lamp biomicroscopy and fundoscopic examina-
tions revealed normal status except for the refractive er-
rors before the study. Because of rapid measurement and
a good correlation with Goldmann applanation tonometer
[21], we used a pneumatic tonometer (NT-530P, Nidek
Co., Ltd, Gamagori, Japan) to measure the IOP in our pa-
tients. Each patient received 3 measurements and the
average of those measurements was the final IOP. The
spherical equivalent was measured and calculated by a
Topcon auto-keratorefractometer (KR-3000, Topcon,
Yamagata, Japan). All the refractions were performed
under cycloplegic condition. If there was an elevation of
IOP more than 5 mmHg compared to baseline, severe al-
lergic reactions or other ocular side effects, we immedi-
ately halted the atropine application and withdrew the
patient from this study. Our subject wore spectacle and
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no contact lens, progressive or photochromic lenses were
applied during the whole follow up period.
Statistical analysis
All statistical analyses were conducted using SPSS soft-
ware version 19 (SPSS Inc., Chicago, Illinois, USA). The
gender and age among groups were evaluated by the
Chi-square test and One-way ANOVA sequentially. For
the comparisons of IOP and refractive errors within each
group during different time periods, the pair-t test was
applied. While comparing the IOP as well as refractive
errors among the three groups, we analyzed the variance
first. If the variances among the three groups were
homogenous, we used One-way ANOVA for analysis
and added Bonferroni test for post-hoc analysis. But if
the variances among the three groups were
heterogenous, we used Welch’s test for analysis and
added Dunnett T3 test for post-hoc analysis. Confidence
intervals of 95 % were regarded as a comparison for
mean values and p < 0.05 was considered statistically sig-
nificant in pair-t test, Chi-square, One-way ANOVA and
Welch’s test but <0.025 in Bonferroni test and Dunnett
T3 test since we need to reduce the family-wise error in
post-hoc exam.
Results
The mean age was 9.03, 8.16 and 8.33 years for the
0.125 % atropine, 0.25 % atropine and control groups,
respectively. There was no statistical significance for
both gender and age (p = 0.50 and 0.37, Chi-square test
and One-way ANOVA sequentially) among the three
groups. The baseline mean intraocular pressure initially
was 13.90 ± 3.26 mmHg in the 0.125 % atropine group,
14.91 ± 3.09 mmHg in the 0.25 % atropine group and
14.50 ± 2.43 mmHg in the control group, respectively.
The mean IOP measurements and the statistical analyses
among the groups during the follow up period are
shown in Table 1. All three groups demonstrated no sig-
nificant difference between group comparisons at each
time point during the study period (Table 1). In addition,
with the exception of the 0.25 % atropine group which
showed a significant difference (p = 0.03) at 3 months,
all three groups during the follow up period demon-
strated no statistically significant difference as compared
to their baseline IOPs (Fig. 1). The data, demonstrated
that a low concentration of atropine use for one year in
school-aged children for myopia control did not induce
IOP elevation.
The baseline mean spherical equivalent was −1.22 ±
0.55 D in the 0.125 % atropine group, −1.45 ± 0.69 D in
the 0.25 % atropine group and −1.45 ± 1.00 D in the con-
trol group, which means none of the groups significantly
differed from the others (p > 0.05). The mean spherical
equivalents and the statistical analyses among the groups
during the follow up period are presented in Table 2.
The mean progression of myopia, i.e., the change of
spherical equivalent, was −0.05 D in the 0.125 % atro-
pine group, 0 D in the 0.25 % atropine group and 1.05 D
in the control group. We found that the spherical equiv-
alents in the atropine groups remained stable (no signifi-
cant difference either between 0.125 % and 0.25 %
atropine groups or compared to their baseline spherical
equivalent at any time point). However, significant pro-
gression of myopia was noted in the control group com-
pared to the 0.125 % atropine group (from 6-month
after treatment till one year) and to the 0.25 % group
(one year) (Fig. 2, p < 0.05). Moreover, a significant dif-
ference in spherical equivalent among three groups was
also noted from 6 months to 12 months with the final
refractive errors of −1.27 ± 0.85 D in the 0.125 % atro-
pine group, −1.45 ± 1.00 D in the 0.25 % atropine group
and −2.50 ± 1.31 D in the control group after treatment
(Table 2, p = 0.03, <0.01 and <0.01, respectively, One-
way ANOVA), indicating that atropine treatment effect-
ively controlled myopia progression.
Discussion
Myopia is one of the most common causes of low vision
in the world [22] and Chinese children and other Asian
populations are more vulnerable to developing myopia,
Table 1 Intraocular pressure measurements and analyses over one year follow up
Group
0.125 % Atropine 0.25 Atropine Control
Mean ± SD (mmHg) Mean ± SD (mmHg) Mean ± SD (mmHg) p
Baseline 13.90 ± 3.26 14.91 ± 3.09 14.50 ± 2.43 0.60
3 Months 14.83 ± 2.43 13.13 ± 3.23a 14.29 ± 2.66 0.18
6 Months 14.19 ± 2.81 14.00 ± 2.09 14.17 ± 2.41 0.98
9 Months 14.05 ± 2.40 13.83 ± 3.10 13.92 ± 2.40 0.97
1 Year 14.44 ± 2.54 13.63 ± 2.64 14.17 ± 2.89 0.66
SD Standard deviation
p = analysis of variance among groups with One-way ANOVA, p < 0.05 demonstrates significant difference among three groups.
aSignificant difference compared to baseline mean IOP was found in the 0.25 % atropine group (p = 0.03), analyzed with the paired t test.
Lee et al. BMC Ophthalmology  (2016) 16:114 Page 3 of 7
as compared to white populations, especially those who
live in urban regions [22–24]. In Taiwan, the myopic
group accounts for a large percentage of school-age chil-
dren, similar to the Chinese population [22, 25]. The
anti-accommodation property of atropine was believed
to retard myopic progression [26], but it has recently
been demonstrated that atropine retards myopia mainly
via a non-accommodative mechanism by regulating the
muscarinic receptor of the retina, choroid and sclera tis-
sues [27–32]. Accumulating evidence has shown that
topical atropine is effective in retarding myopic progres-
sion [1, 5, 8, 12, 33]. Kennedy et al. [34] revealed that
mean myopic progression during atropine treatment was
0.05 D per year, whereas the control group had an an-
nual progression of 0.36 D. Moreover, Chua et al. con-
cluded that atropine not only retards the progression of
myopia but also reduces the axial length elongation [5].
In our study, the mean progression of myopia evidenced
no significant difference compared to the baseline in the
0.125 % and 0.25 % atropine groups, though the control
group showed a significant progression (p < 0.01) during
the follow up period. Our study is consistent with
others, implying that atropine treatment may prevent
myopia progression.
It was also demonstrated that a higher concentration of
atropine use results in better myopia control [5, 6, 8, 35]
Fan et al. used 1 % atropine and found that progression of
myopia was +0.06 ± 0.79 D in the treatment group versus-
1.19 ± 2.48 D in control group per year [6]. Chua et al. also
reported a 0.92 D difference in myopic progression be-
tween the treatment group (1 % atropine) and control
group [5]. In addition, Song et al. demonstrated that high
concentrations (0.5 % and 1 %) were more effective to re-
tard myopia progression than lower concentrations
(0.05 %, 0.1 % and 0.25 %) [8]. A similar study by
Shih et al. showed that 61 % of patient in the 0.5 %
atropine group had no myopia progression, compared
to 49 % in 0.25 % atropine group and 42 % in 0.1 %
atropine group, thus indicating that higher concentra-
tions are more effective [35]. However, side effects
such as mydriasis, photophobia, blurred vision and al-
lergic dermatitis by high concentration atropine have
been reported [1, 7] which may limit the medication
Fig. 1 Mean intraocular pressure (IOP) in the three groups during the follow up period. *denotes significant difference compared to baseline
mean IOP in the 0.25 % atropine group
Table 2 Mean spherical equivalent in each group before and
after atropine treatment
Group
0.125 % Atropine 0.25 Atropine Control
Mean ± SD (D) Mean ± SD (D) Mean ± SD (D) p
Baseline −1.22 ± 0.55 −1.45 ± 0.69 −1.45 ± 1.00 0.52
3 Months −1.16 ± 0.63 −1.48 ± 0.72 −1.85 ± 1.17Ø 0.13
6 Months −1.22 ± 0.70 −1.43 ± 0.80 −2.03 ± 1.28Ø 0.03a
9 Months −1.19 ± 0.80 −1.42 ± 0.86 −2.20 ± 1.27Ø <0.01a
1 Year −1.27 ± 0.85 −1.45 ± 1.00 −2.50 ± 1.31Ø <0.01a
D Diopter, SD Standard deviation
Analyses of variance among the three groups were performed with the
One-way ANOVA and Welch’s test, a indicates significant difference among
three groups (p < 0.05)
Analyses of variance from baseline within the group were performed with the
paired t test; ØSignificant difference from baseline spherical
equivalent (p < 0.05)
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compliance [35] and impose psychological burdens on
the parents. Cooper et al. demonstrated that 0.02 %
atropine is the maximum dose that would not induce
clinical symptoms [36], and for this reason, low atro-
pine dose should probably be considered so as to
limit adverse effects. In addition, lower concentrations
of atropine may also effectively retard myopia pro-
gression even at a concentration of 0.01 % [20]. In
our study, we found no significant difference between
the 0.125 % atropine and 0.25 % atropine groups (p >
0.025) with a mean myopic progression of −0.05D in
the 0.125 % atropine group and 0D in 0.25 % atro-
pine group for the one year follow up period. Taken
together, we recommend that a low concentration at-
ropine should be considered first in terms of retard-
ing myopia progression and avoiding intolerable side
effects.
One of the controversial side effects of atropine is its
anti-cholinergic effect that leads to drug-induced acute
angle closure glaucoma [10]. Although Herring et al.
[37] found an IOP decrease in horse eyes after 1 % top-
ical atropine use, Stadtbaumer [38] observed an IOP ele-
vation in feline eyes from the same medication. The
same inconsistency was also noted in human eyes.
Harris et al. showed that atropine may lead to the eleva-
tions of IOP up to 23 % in proven open-angle glaucoma,
but only 2 % in an apparently normal population [39].
Hadjikoutis et al. suggested careful use of atropine in
neurological operation to prevent elevated IOP and
angle closure glaucoma in susceptible patients [40].
However, the threshold concentration that may lead to
such side effects was not disclosed in these studies. In a
large scale study, Wu et al. [41] analyzed 621 myopic
children with atropine dosages ranging from 0.1 % to
1 % and concluded that neither the duration of treat-
ment nor cumulative dose of atropine would statistically
elevate IOP. In our study, there was no IOP elevation in
atropine treatment groups compared to either baseline
measurements or to control group during the one year
follow up. Though our results were consistent with
those of Wu et al., our study was prospective-designed
while their study was retrospective in nature. In
addition, we used the average data of three measure-
ments from every visit compared to only one digital
reading by Wu et al., which may have increased their
measurement errors. Therefore, these studies on school-
aged children do not support the linkage between atro-
pine use and the elevation of IOP in normal eyes.
It would be interesting to know if there is any relation-
ship between intraocular pressure and myopia progres-
sion. Jensen et al. [42] concluded that IOP-lowering eye
drops demonstrated no effectiveness on retarding my-
opic progression and indicated that IOP has no signifi-
cant relation with myopia progression. However, a later
study conducted by the same team revealed that if IOP
was above 16 mmHg, a statistically significant difference
of myopia progression would appear (1.32D in 2 years
versus 0.86D in 2 years) [43]. The authors thus sug-
gested using IOP measurements in studying myopia pro-
gression. A more recently study revealed that IOP would
Fig. 2 Mean spherical equivalent in the three groups during the follow up period. * indicates significant difference between 0.125 % atropine
group and control group; # demonstrates significant difference between 0.25 % atropine group and control group
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elevate after onset of myopia [44], though the relation-
ship between IOP and refractive error remain unclear
[45]. Our study did not evidence the relationship be-
tween IOP elevation and myopic progression in one year
period, which probably because myopia progression was
reduced in the 0.25 % and 0.125 % atropine groups.
However, one should keep in mind that myopia may lead
to IOP elevation and current study only showed that at-
ropine didn’t contribute to IOP elevation. Therefore, fur-
ther long-term study is mandatory to investigate the
incidence and risk factors of myopic-induced glaucoma.
There are some limitations in our study. First, this
study is not a double-blind randomized design. Second,
the small sample size and relatively short follow up time
are noted in our study. Long term side effects may be
apparent in a long period of follow up.
Conclusions
In conclusion, when it comes to the elevation of intraoc-
ular pressure, there was no evidence that ocular hyper-
tension would be increased by the application of
atropine for one year in this study. Similar to other stud-
ies, topical atropine eye drop is effective in slowing the
progression of low to moderate myopia even with a low
concentration of 0.125 %. Therefore, low concentration
atropine may be used in clinical practice to retard my-
opia. However, randomized controlled clinical trials with
a large sample size and long follow up should be con-
ducted in the future to validate our results.
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